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Background: The prevalence of death due to cardiovascular disease increases steeply in vascular surgery patients with
increasing age. Observational data in coronary heart disease and heart failure patients suggest that elderly patients are less
optimally treated compared to younger patients. The aim of this study was to examine the differences in clinical
characteristics and medical therapy of the elderly compared to younger patients in vascular surgery. Furthermore, we
assessed the effect of statins on 1-year mortality in an unselected patient population.
Methods: Data on 711 consecutive peripheral vascular surgery patients were collected from 11 hospitals in The
Netherlands in 2004. Elderly patients were defined as patients with an age above 70 years. Multivariable logistic
regression analysis was used to identify clinical characteristics and medical therapy associated with older age. The effect
of statins on 1-year mortality was assessed with Cox proportional hazard regression analysis.
Results: The mean age was 67  10 years and 299 (42%) patients were older than 70 years of age. Elderly patients showed
a significant higher cardiac risk profile according to the Lee Cardiac Risk Index (Lee-Index) (>2 risk factors: 50% vs 32%
in younger patients, P < .001). Multivariable analysis showed that older patients presented with a significant higher
Lee-Index, a higher incidence of cardiac arrhythmias (odds ratio [OR]  1.9; 95% confidence interval [CI]  1.1-3.3) and
chronic obstructive pulmonary disease (COPD) (OR  2.8; 95% CI  1.7-4.7). However, smoking (OR  0.5; 95% CI 
0.3-0.7) was less common in the elderly. Statins were significantly less often prescribed in the elderly (OR  0.6; 95% CI 
0.4-0.8), although a beneficial effect of statins on 1-year mortality (HR  0.3, 95% CI  0.1-0.7) was observed.
Conclusion: Elderly patients undergoing vascular surgery had a higher cardiac risk profile than younger patients. Despite
this high cardiac risk and the beneficial effect, our study demonstrated that statins were less often used in elderly patients.
( J Vasc Surg 2008;48:891-6.)Cardiovascular disease remains the major cause of death
and morbidity across Europe. The global aging phenomenon
will even further increase the burden of cardiovascular disease.
Overall, approximately 40% of deaths are caused by cardiovas-
cular diseases, with a prevalence of up to 50% in the elderly.1,2
Aging of the world’s population can be seen as an
indicator of improving global health. A high standard of
living and the good quality of health care have contributed
to the increased life expectancy.1 On the other hand, aging
also enforces a change in health care toward the elderly
population. In contrast to the past, major surgical interven-
tions are increasingly performed in the elderly. Furthermore, a
recent study performed in 1351 patients undergoing non-
cardiac surgery showed that the rate of cardiac events in-
creased with advanced age, independent of other clinical vari-
ables, in patients with myocardial perfusion abnormalities
during stress scintigraphy.3 Despite this increased cardiovas-
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ogy suggest that evidence-based therapies are less frequently
used in the elderly population.4-6 A major point of discussion
in this context is the effectiveness of medical therapy in the
elderly. More research is conducted in the elderly these days
and, for example, statins have shown to be also beneficial in
the increasing group of coronary artery disease patients with
advanced age.7
The aim of this study was to examine the differences in
clinical characteristics and medical therapy of the elderly
compared to younger patients in vascular surgery. Further-
more, we assessed the effect of statins on 1-year mortality in
an unselected patient population.
METHODS
Study population. Between May and December 2004,
a survey of clinical practice was conducted in 11 hospitals in
The Netherlands.8 A total of 711 patients were consecu-
tively enrolled. This survey was an integral part of the
infrastructure of the survey program supported by The
Netherlands Heart Foundation in the context of the Euro
Heart Survey Programme.
All patients who were admitted to the vascular surgery
department of the participating hospitals were screened.
Patients undergoing peripheral vascular repair were eligible
for participation in the survey. The medical ethics commit-
tees of the participating hospitals approved the study and
patients provided informed consent.
Data collection. Trained research assistants obtained
data on patient characteristics, diagnostic procedures, car-
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the patients’ hospital charts. All data were entered into an
electronic Case Record Form (eCRF) and transferred reg-
ularly to the central database at Erasmus MC via the Inter-
net. Data entered into the eCRF were automatically
checked for completeness, internal consistency, and accu-
racy. The data management staff at Erasmus MC performed
additional edit checks. If necessary, queries were resolved
with the local research assistants.
Clinical characteristics. In this study, advanced age
was defined as above 70 years of age. We determined the
cardiac risk score for each patient in our dataset, according
to the Lee Cardiac Risk Index (Lee-Index),9 and one point
was assigned to each of the following characteristics: open
vascular surgery, history of ischemic heart disease, history of
congestive heart failure, history of cerebrovascular disease,
insulin-dependent diabetes mellitus, and renal insufficiency.
Hypertension was recorded if patients presented with a blood
pressure 140/90 mm Hg or if patients were medically
treated for hypertension. Diabetes mellitus was recorded if
patients presented with a fasting glucose level7.0 mmol/L,
or in those who required treatment. Renal insufficiency was
recorded if patients presented with a serum creatinine level
2.0 mg/dL or in those who required dialysis. Obesity was
defined as having a Body Mass Index30 kg/m2.
Follow-up. The endpoint of this study was 1-year
mortality after surgery.
Statistical analyses. Dichotomous data are described
as numbers and percentages. Differences in baseline char-
acteristics between young and elderly patients were evalu-
ated by 2 tests. Logistic regression analysis was used to
identify clinical characteristics and medical therapy (statins,
beta-blockers, antiplatelet agents) associated with advanced
age as the dependent variable. The clinical characteristics
included in the model were: gender, obesity, smoking,
hypertension, arrhythmia, valvular disease, chronic ob-
structive pulmonary disease (COPD), and Lee-Index. In-
teraction terms were included if statistically significant.
Furthermore, the effect of statins on 1-year mortality in a
consecutive cohort was evaluated with Cox proportional
hazard regression analysis including an interaction term of
statin therapy and advanced age. Odds ratios (OR) and
hazard ratios (HR) are reported with corresponding 95%
confidence interval (CI). For all tests, a P-value  .05
(two-sided) was considered significant. All statistical analy-
ses were performed using SPSS statistical software, (Chi-
cago, Ill).
RESULTS
The mean age of the 711 patients was 67  10 years
and 299 (42%) patients were older than 70 years of age
(Table I). Half of the patients underwent an endovascular
procedure (n 354), 328 patients (46%) had open surgery,
and 29 patients (4%) underwent carotid endarterectomy.
Elderly patients showed a significantly higher cardiac risk
profile according to the Lee-Index (2 risk factors: 50% vs
32%, P  .001). The main contributable factors in the
Lee-Index were history of ischemic heart disease (42% vs30%, P  .001), heart failure (9% vs 3%, P  .001) and a
history of a cerebrovascular event (21% vs 15%, P  .024).
Logistic regression analysis with advanced age as the
dependent variable showed that elderly patients presented
with a significantly higher Lee-Index (1 risk factor: OR 
1.2, 95% CI 0.8-1.9; 2 risk factors: OR 2.0, 95% CI
1.3-3.1; 2 risk factors: OR  2.8, 95% CI  1.5-5.4)
compared to younger patients. Also a higher incidence of
cardiac arrhythmias (OR  1.9, 95% CI  1.1-3.3) and
COPD (OR 2.8; 95% CI 1.7-4.7) was observed in the
elderly. However, smoking (OR 0.5, 95% CI 0.3-0.7)
was less common in the elderly. A significant interaction
term was observed between smoking and COPD (OR 
0.2; 95% CI  0.04-0.6). These numbers are visualized in
Fig 1.
Of the total population, 48% received beta-blockers, 56%
statins, 81% antiplatelets, and 59% anticoagulants. Beta-block-
ers were more often prescribed in elderly patients (53% vs 44%,
P  .033), while statins were less common used in these
patients (51% vs 60%, P .012); Table II). Analysis adjusted
for patient characteristics showed that statins were signifi-
cantly less often prescribed in the elderly (OR  0.6; 95%
CI 0.4-0.8), whereas no differences in prescription of other
cardiovascular drugs were observed (Fig 2). As shown in Fig 3,
statin use was clearly associated with age. Until the age of 60,
we observed an evident increase of statin prescription, whereas
afterwards a decline was noticed.
The use of statins was associated with a beneficial effect
on 1-year mortality (HR  0.3, 95% CI  0.1-0.7). No
significant interaction was observed between advanced age
Table I. Baseline characteristics
Age 70
years
Age 70
years
P-value
412,
n (%)
299,
n (%)
Male gender 285 (69) 211 (70) .690
Current smoker 176 (43) 80 (27) .001
Hypertension 157 (38) 116 (39) .852
Diabetes mellitus 82 (20) 67 (22) .418
Renal insufficiency 18 (4) 33 (11) .001
Angina pectoris 54 (13) 45 (15) .460
Myocardial infarction 50 (12) 56 (19) .015
Heart failure 11 (3) 27 (9) .001
Stroke or TIA 60 (15) 63 (21) .024
Previous revascularization 57 (14) 59 (20) .036
COPD 43 (10) 58 (19) .001
Lee-Indexa .001
0 127 (31) 60 (20)
1 152 (37) 91 (30)
2 108 (26) 113 (38)
3 25 (6) 35 (12)
TIA, Transient ischemic attack; COPD, chronic obstructive pulmonary
disease; Lee-Index, Lee Cardiac Risk Index.
aVariables included in the Revised Cardiac Risk Index: open surgical proce-
dure, ischemic heart disease, history of congestive heart failure, history of
cerebrovascular disease, insulin therapy for diabetes mellitus, and renal
insufficiency.and statin therapy.
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Elderly patients undergoing vascular surgery had a
higher cardiac risk profile than younger patients. Despite
this high cardiac risk and the observed beneficial effect of
statins, our study demonstrated that statins were less often
prescribed in elderly patients.
An important observation of our study is that 42% of our
vascular surgery patients consisted of patients over the age of
Fig 1. Clinical risk factors associated with elderly age.
Table II. Medical treatment
Age 70 years Age 70 years
P-value
412,
n (%)
299,
n (%)
Beta-blockers 183 (44) 157 (53) .033
Statins 247 (60) 151 (51) .012
Platelet inhibitors 335 (81) 240 (80) .727
Fig 2. Association of the prescription of medical therapy with
elderly age.70. This number clearly reflects the overall aging phenome-non and also emphasizes the increasing proportion of elderly
people undergoing surgery. Advanced age has shown to be an
important predictor of adverse outcome in patients undergo-
ing vascular surgery.10,11 Boersma et al demonstrated that
adding advanced age to the Lee-Index increased its predictive
value of cardiovascular mortality. The combination of the
high incidence of co-morbidities in the elderly and the effect
of aging itself poses this elderly population as a high-risk
group. Our study confirms that patients with advanced age
have a higher cardiac risk profile according to the Lee-Index as
compared to the younger group. Furthermore, beyond the
Lee-Index, COPD and cardiac arrhythmias were significantly
associated with advanced age in our study which is also well-
known from literature.12 Evidently, this elderly population is
an increasing high risk population which should get extra
attention in the coming years.
Statins are widely prescribed in patients with or at risk
for coronary heart disease (CHD) because of their well-
established lipid lowering capacity. Beyond this property, ef-
fects of statins as atherosclerotic plaque stabilization, oxidative
stress reduction, and a decrease of vascular inflammation may
stabilize coronary artery plaques and thereby prevent plaque
rupture and subsequent myocardial infarction (MI) in the
peri-operative period.13 Several studies indeed showed a ben-
eficial effect of statins in vascular surgery patients.14-18 Our
observational study in a consecutive cohort of patients seen in
daily clinical practice confirms that the use of statins is associ-
ated with reduced mortality. Based on this accumulating
evidence, the recently published guidelines on peri-operative
cardiovascular evaluation and care recommend statin treat-
ment in all patients undergoing vascular surgery.19
Despite the benefits of statins on cardiovascular events,
we observed that statins were significantly less often pre-
scribed in elderly patients undergoing vascular surgery. Pa-
tients with advanced age were almost two times less likely to
receive statins in the peri-operative period. To our knowledge,
this is the first study reporting on the under use of statins in
elderly patients undergoing vascular surgery. This is in con-
trast to CHD and heart failure patients where the undertreat-
Fig 3. Proportion of patients with statin therapy by age groups.ment phenomenon in the elderly is widely described.5,20-22 A
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65-74 years were half as likely to receive statins as those aged
under 65 years while patients aged 75 years were nine times
less likely.21 Moreover, an overall increase in prescription of
statins in CHD patients was shown over time in different
studies, but importantly the substantial age inequalities in
statin use changed little in the last decade.5,22
Different factors may contribute to the low prescription
rates in the elderly. First, an important reason is the short-
age of evidence in the elderly population as a result of a
historical under-representation of this group in random-
ized controlled trials. These highly selective trial popula-
tions lessen generalizability to clinical practice which rep-
resents a rather heterogeneous population. A recent study
investigating the underutilization of statins in elderly cor-
onary heart disease patients revealed that the primary rea-
son why elderly patients not receiving statins were per-
ceived lack of indication.23 In recent years, however, more
research is conducted in the elderly. To answer the question
of statins in elderly patients with CHD, Afilalo et al7
conducted a hierarchical bayesian meta-analysis including
nine randomized trials with an age range of 65 to 82 years.
They demonstrated a beneficial effect of statins in the
elderly and reported a relative reduction of 22% over 5 years
(relative risk [RR]  0.8, 95% CI  0.7-0.9) for all causes
of mortality. In addition, statins reduced CHD mortality,
non-fatal MI, the need for revascularization, and stroke.
Furthermore, a large cohort study indicated that statin
therapy was beneficial across all age groups up to 97 years of
age with the greatest absolute benefit in the very elderly
patients.20 Importantly, our study in an unselected cohort
of vascular surgery patients indicated a comparable signifi-
cant effect of statin therapy in the elderly compared to
younger patients. Although limited by the observational
nature of this study, these results hint to extend the effect of
statins to patients with advanced age undergoing vascular
surgery. As elderly patients have a higher baseline risk,
which is also demonstrated in this study, this comparable
effect of statins in the elderly will logically result in a greater
absolute risk reduction. Furthermore, baseline risk has
shown to outweigh potential age-related variations in the
efficacy of treatment for the absolute benefits of treat-
ment.24
There may also be a greater fear of side effects in the
elderly population, mainly because of polypharmacy and
comorbidities. The LIPID study and the Cholesterol Re-
duction in Seniors Program, however, showed a compara-
ble incidence of adverse events in young and elderly pa-
tients.25,26 Results of the Study Assessing Goals in the
Elderly (SAGE) indicated that statins were well tolerated in
older patients.27 Furthermore, the Prospective Study of Prav-
astatin in the Elderly at Risk (PROSPER) trial showed no
effect of polypharmacy on pravastatin functioning.28 And
again, because of the high baseline risk in the elderly, the
treatment-related adverse effects exert relatively little influence
on the net benefits associated with treatment.
Cost-effectiveness may be another point of concern
which may relate to the under use of statins. Studies indi-cate, however, that statin therapy is reasonably cost-effective
in the elderly and at least comparable to younger patients. The
estimated cost-effectiveness ratio of statin therapy in patients
aged 75 to 84 years of age with a history of MI was 18,800
per quality-adjusted life year.29 This number is quite similar to
the ratio in younger patients.30 Important to note is that
cost-effectiveness is also a function of baseline risk, ie, the high
baseline risk of the elderly patient will lead to more favourable
cost-effectiveness ratios because a greater absolute number of
events would be prevented.
To summarize, our study shows a high proportion of
elderly undergoing vascular surgery and indicates that sta-
tin therapy seems to be as beneficial in elderly patients as
compared to younger patients. This is a crucial fact in a
future with increasing life expectancy and rising number of
the elderly population. Despite the increased risk of the
elderly and the observed beneficial effect of statins in this
population, our study revealed that statins were signifi-
cantly less often used in elderly patients undergoing vascu-
lar surgery. More research is needed to further investigate
the effect of statin therapy in the elderly in randomized
controlled trials and guideline implementation strategies
should be improved to increase the prescription of statins in
this high risk population.
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Under use of statins in the elderly: The need for better health
care services research
The past thirty years have witnessed remarkable advances inmost important is the development of the HMG Co-A reductase
inhibitors, or “statins”. These medications have demonstrated
significant and consistent reductions in morbidity and mortality for
all patients with atherosclerotic disease. They are associated with a
